Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06211569
Recruiting Observational

Study of the Prevalence of Endometriosis and Adenomyosis

NCT06211569 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2024-04-04
Last updated
2026-04-16

Condition(s) studied

Elective Fertility Preservation

Investigational drug(s) / intervention(s)

Usual follow-up

Usual follow-up: Usual follow-up

Study summary

Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.

Eligibility

Sex
FEMALE
Min age
29 Years
Max age
37 Years
Healthy volunteers
No
Inclusion Criteria: * Woman aged between 29 and 37 * Consultant for non-medical fertility preservation in the Reproductive Medicine Unit Port Royal, Cochin * Informed and not opposed to this research * Affiliated to a social security scheme Exclusion Criteria: * Pregnant women * Refusing to take part in the study * Under court protection, curatorship or guardianship * Women with a known malformation of the genital tract

Primary outcome measure(s)

  • Transvaginal pelvic ultrasound — Up to month 6
    Search for endometriosis and adenomyosis on transvaginal pelvic ultrasound and characterisation of lesions.

Trial sites (1)

FacilityCityRegionStatus
Gynécologie Obstétrique II et médecine de la reproduction, Hôpital Cochin, Port Royal Paris Île-de-France Region Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Prospective Longitudinal Cohort Study of Vasculitis Patients Recruiting
Quality of Life of Caregivers Supporting an Older Adult With Cancer Starting soon
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy Recruiting
Certolizumab in Recurrent Implantation Failure (RIF) Recruiting
Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06211569 on ClinicalTrials.gov ↗ ← All trials in France